Clinical Trials Logo

Clinical Trial Summary

This is a Phase I study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ). Eligible patients must have histologically proven newly diagnosed, O6-methylguanine-DNA methyltransferase (MGMT) methylated WHO grade III or IV astrocytoma and be planning to undergo treatment with standard adjuvant TMZ (after completing treatment with TMZ and ionizing radiation (IR)). During this study, patients will receive daily oral ACZ with TMZ. During each cycle, ACZ will be started on the day of TMZ initiation and continued for a total of 21 days.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03011671
Study type Interventional
Source University of Chicago
Contact Bakhtiar Yamini, M.D.
Phone 773-702-2123
Email byamini@surgery.bsd.uchicago.edu
Status Recruiting
Phase Phase 1
Start date October 3, 2018
Completion date October 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05686798 - Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. Phase 1
Recruiting NCT02617134 - CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor Phase 1/Phase 2
Completed NCT03355794 - A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Phase 1
Recruiting NCT04937244 - Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas Phase 4
Recruiting NCT03423992 - Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas Phase 1
Not yet recruiting NCT04482933 - HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma Phase 2
Not yet recruiting NCT06417281 - Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid(5-ALA) Phase 3
Withdrawn NCT03176160 - LITT Palliative Treatment for Patients With Malignant Gliomas
Recruiting NCT02839954 - CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor Phase 1/Phase 2
Recruiting NCT03152318 - A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 Phase 1
Completed NCT00870181 - ADV-TK Improves Outcome of Recurrent High-Grade Glioma Phase 2
Completed NCT01550523 - Pilot Immunotherapy Trial for Recurrent Malignant Gliomas Phase 1
Terminated NCT01017653 - Panitumumab and Irinotecan for Malignant Gliomas Phase 2